Docebo: Earnings Beat And Buyback Signal The Market Is Underpricing The Turn, But Leverage Is A Trap

Upgrade to Buy. Docebo beat Q2 earnings by roughly 17%, reaccelerated recurring revenue, and announced a $70 million share buyback at $20.40 — a price the board considers a floor on its own business. At $22.30 and a trailing P/E of 16x, the stock offers a valuation gap between the selloff and the underlying operating improvement. The risk is leverage, not growth.

The move

Docebo (NASDAQ: DCBO) is up 8.9% today after reporting Q2 2026 results before market open. The stock sits at $22.30, down 27.5% over the trailing 12 months and still roughly 32% below its 52-week high of $32.85. Year-to-date it is basically flat. The market has spent most of the year discounting this $566 million company as a slow-growth LMS (learning management system) player with concentration risk and fading AI narrative. The Q2 print argues the discount went too far.

What changed

Earnings per share of $0.35 versus the consensus estimate represents a beat of roughly 17%. Total revenue came in at $67.8 million, above the street estimate of roughly $67.1 million. Subscription revenue — the recurring base that matters most for a SaaS business — grew 11.2%–11.6% year-over-year to the $63.5M–$63.7M range.

More important than the headline beat is the direction of recurring revenue. Annual Recurring Revenue (ARR — the annualized equivalent of subscription contracts, a proxy for the health and momentum of the recurring base) reached $255.1 million, up 9.5% year-over-year. That is the second consecutive quarter of ARR reacceleration, driven by broad-based strength across net new bookings, expansion revenue, and international sales.

Adjusted ARR growth — stripping out FX headwinds, acquired ARR, and the largest OEM customer — was approximately 13.9%. That is the number that tells you whether the core business is still compounding. It is.

Customer concentration, one of the persistent overhangs on this stock, has meaningfully declined. The largest OEM customer now represents 2.5% of ARR, down from 8.4% a year ago. Management expects OEM revenue to stay at 3%–4% of total revenue for the full year. The concentration discount is evaporating.

Adjusted EBITDA (earnings before interest, taxes, depreciation, amortization, and certain non-cash items — a rough cash-earnings proxy) came in at roughly $11 million, up roughly 20% year-over-year. Management lifted full-year revenue guidance by $3.5 million to $274.5M–$276.5M but held EBITDA guidance flat at $54.5M–$56.5M, pointing to near-term investments in healthcare expansion and a new Forward-Deployed Engineer model that will initially hit R&D expenses.

Free cash flow is the hidden line

Trailing-twelve-month free cash flow stands at $44.2 million, up 61.3% year-over-year, with a free cash flow margin of 17.6%. Gross margin remains at 79.8%, and the operating margin sits at 8.0%. For a company with a $255 million ARR base, that FCF conversion rate — roughly 17% of revenue flowing to cash — is the operating leverage argument the market hasn't priced in.

Return on invested capital (ROIC) at 52.4% is unusually high for a company of this size, signaling that the capital already in the business is working efficiently. The business generates cash; it doesn't consume it.

The buyback

On July 17, the board approved a Substantial Issuer Bid to repurchase up to $70 million of shares, representing approximately 13.8% of outstanding shares. Funding comes from roughly $10 million in cash on hand and $60 million from an expanded credit facility (raised from $100 million to $150 million). The majority shareholder, Intercap Inc. (which owns roughly 63.9% of the company), intends to participate to maintain its ownership percentage.

The board's decision to fix the repurchase price at $20.40 is not an arbitrary number. It is a signal that management considers the stock materially undervalued below that level. The buyback is also meaningful in scale: $70 million on a $566 million market cap is a 12% potential reduction in share count. That alone would boost per-share earnings power if the business holds steady.

Valuation versus the SaaS pack

At current levels, Docebo trades at 16.4x trailing earnings, 2.25x trailing sales, and roughly 30x EV/EBITDA. The PEG ratio (P/E divided by growth rate) is 0.28x — a number that signals the market is paying far less than one dollar of earnings for each percentage point of growth.

For context, compare the valuation picture:

Metric	Docebo (DCBO)	Atlassian (TEAM)
Market Cap	$566M	$37.8B
P/E TTM	16.4x	Negative (unprofitable)
P/S TTM	2.25x	5.76x
EV/EBITDA	30.2x	261.2x
FCF Margin	17.6%	N/A (negative)

Docebo trades at a fraction of the multiple that investors pay for larger software peers, yet it already generates positive free cash flow at a 17.6% margin. Atlassian — the closest category peer in enterprise workforce technology — trades at a 5.8x revenue multiple despite not yet printing GAAP profit. The divergence is striking, but it is also explicable: Docebo is a small-cap with leverage, governance concerns, and a recent history of disappointing quarters. The discount is real. The question is whether it is permanent.

Risks that matter

Three items prevent this from being a simple "buy the dip" call.

Leverage is the real problem. Total debt stands at $254.2 million against cash of $63.2 million. Net debt is roughly $15.9 million, which looks manageable, but total equity is effectively negative at -$0.6 million due to accumulated share repurchases and retained earnings dynamics. The debt-to-equity ratio is technically nonsensical because equity is negative — which means the balance sheet is thin. The $60 million drawn from the credit facility for the buyback will add to this. The company is borrowing to repurchase its own stock while sitting on a fragile equity base. That is a move that rewards shareholders only if earnings power continues to compound. If it stalls, leverage becomes a liability fast.

AI is product, not proof yet.AgentHub and Enterprise Knowledge are scheduled for a fall launch, and management is investing in a Forward-Deployed Engineer model to build custom AI workloads for verticals like healthcare, financial services, and quick-service restaurants. The 365Talents acquisition (closed in January 2026) is ahead of schedule on integration. These are credible product bets. But none of them appear in the Q2 revenue number, and management explicitly said the healthcare vertical requires "significant investment" with no immediate financial returns. The FDE model will initially increase R&D costs before shifting to COGS. Near-term margin pressure is baked in.

Easier comps are fading. Management flagged on the call that ARR reacceleration is partly driven by lapping the AWS and Dayforce headwinds that hit the same period a year ago. The comparisons won't stay this favorable. Q3 guidance — $69.5M–$69.7M in revenue — implies revenue growth of roughly 11%–12% versus Q3 2025, which is solid but not a dramatic step up.

The catalyst clock

Q3 2026, reporting around November, is the next inflection point. FedRAMP Moderate certification is feeding an enterprise pipeline — management noted that roughly 80% of enterprise deals now involve partners including Deloitte and NIIT. If that pipeline converts at pace, Q3 revenue will land at the top end of guidance and EBITDA will benefit from the seasonal Q3 bump (Q3 guidance calls for $15.9M–$16.1M in adjusted EBITDA, roughly 40% higher than Q2).

The fall launch of AgentHub and Enterprise Knowledge is the second near-term catalyst. Even soft early adoption would provide evidence that the AI narrative is moving from marketing to revenue.

Verdict

Docebo's Q2 report shows a business that is reaccelerating on ARR, de-risking customer concentration, generating cash at a 17.6% margin, and trading at a trailing P/E of 16x. The $70 million buyback at $20.40 anchors the downside. The growth narrative has evidence behind it — second-quarter reacceleration, enterprise pipeline depth, declining OEM concentration — rather than resting on AI product launches that haven't arrived.

The leverage profile is the objection. A negative equity base and $254 million in debt are not features you ignore. But on a $44 million free cash flow run rate, the company generates enough cash to service its obligations. The buyback is aggressive but not reckless if the revenue trajectory holds.

Rating: Buy. The stock is trading below the price at which the board is willing to repurchase its own shares. The operating metrics support a re-rating. Monitor Q3 enterprise deal conversion and the AgentHub launch in Q4 for the next proof points. If debt servicing costs accelerate or the FDE model burns through R&D without converting to revenue by mid-2027, the rating would flip to Hold.